{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:07:59Z","timestamp":1789398479600,"version":"build-2803163510"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medicines Development for Global Health"},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X020258\/1"],"award-info":[{"award-number":["MR\/X020258\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-030046"],"award-info":[{"award-number":["INV-030046"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Concerns that annual mass administration of ivermectin, the predominant strategy for onchocerciasis control and elimination, may not lead to elimination of parasite transmission (EoT) in all endemic areas have increased interest in alternative treatment strategies. One such strategy is moxidectin. We performed an updated economic assessment of moxidectin- relative to ivermectin-based strategies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We investigated annual and biannual community-directed treatment with ivermectin (aCDTI, bCDTI) and moxidectin (aCDTM, bCDTM) with minimal or enhanced coverage (65% or 80% of total population taking the drug, respectively) in intervention-naive areas with 30%, 50%, or 70% microfilarial baseline prevalence (representative of hypo-, meso-, and hyperendemic areas). We compared programmatic delivery costs for the number of treatments achieving 90% probability of EoT (EoT90), calculated with the individual-based stochastic transmission model EPIONCHO-IBM. We used the costs for 40 years of program delivery when EoT90 was not reached earlier. The delivery costs do not include drug costs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>aCDTM and bCDTM achieved EoT90 with lower programmatic delivery costs than aCDTI with 1 exception: aCDTM with minimal coverage did not achieve EoT90 in hyperendemic areas within 40 years. With minimal coverage, bCDTI delivery costs as much or more than aCDTM and bCDTM. With enhanced coverage, programmatic delivery costs for aCDTM and bCDTM were lower than for aCDTI and bCDTI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Moxidectin-based strategies could accelerate progress toward EoT and reduce programmatic delivery costs compared with ivermectin-based strategies. The costs of moxidectin to national programs are needed to quantify whether delivery cost reductions will translate into overall program cost reduction.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae054","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T16:32:10Z","timestamp":1714062730000},"page":"S138-S145","source":"Crossref","is-referenced-by-count":7,"title":["An Updated Economic Assessment of Moxidectin Treatment Strategies for Onchocerciasis Elimination"],"prefix":"10.1093","volume":"78","author":[{"given":"Hugo C","family":"Turner","sequence":"first","affiliation":[{"name":"UK Medical Research Council Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London , London , United Kingdom"},{"name":"London Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klodeta","family":"Kura","sequence":"additional","affiliation":[{"name":"UK Medical Research Council Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London , London , United Kingdom"},{"name":"London Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Roth","sequence":"additional","affiliation":[{"name":"Medicines Development for Global Health , Melbourne, Victoria , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette C","family":"Kuesel","sequence":"additional","affiliation":[{"name":"UNICEF\/United Nations Development Progamme\/World Bank\/World Health Organization Special Programme for Research and Training in Tropical Diseases, World Health Organization , Geneva , Switzerland (retired)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Kinrade","sequence":"additional","affiliation":[{"name":"Medicines Development for Global Health , Melbourne, Victoria , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5031-3361","authenticated-orcid":false,"given":"Maria-Gloria","family":"Bas\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"UK Medical Research Council Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London , London , United Kingdom"},{"name":"London Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"2024042516222799300_ciae054-B1","first-page":"9","article-title":"Human onchocerciasis\u2014an overview of the disease","volume":"59","author":"Duke","year":"1990","journal-title":"Acta Leiden"},{"key":"2024042516222799300_ciae054-B2","author":"World Health Organization"},{"key":"2024042516222799300_ciae054-B3","first-page":"405","article-title":"Progress toward elimination of onchocerciasis in the Americas\u20141993\u20132012","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"Morb Mortal Wkly Rep"},{"key":"2024042516222799300_ciae054-B4","first-page":"453","article-title":"Progress in eliminating onchocerciasis in the WHO region of the Americas: advances towards interrupting the transmission of onchocerciasis from the latest preliminary serological assessments conducted in parts of the Yanomami focus area, 2018\u20132022","volume":"98","author":"World Health Organization","year":"2023","journal-title":"Wkly Epidemiol Rec"},{"key":"2024042516222799300_ciae054-B5","first-page":"567","article-title":"Elimination of human onchocerciasis: progress report, 2022\u20132023","volume":"98","author":"World Health Organization","year":"2023","journal-title":"Wkly Epidemiol Rec"},{"key":"2024042516222799300_ciae054-B6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0065-308X(05)61009-3","article-title":"Control of onchocerciasis","volume":"61","author":"Boatin","year":"2006","journal-title":"Adv Parasitol"},{"key":"2024042516222799300_ciae054-B7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1179\/136485908X337418","article-title":"The Mectizan Donation Program: 20 years of successful collaboration\u2014a retrospective","volume":"102","author":"Colatrella","year":"2008","journal-title":"Ann Trop Med Parasitol"},{"key":"2024042516222799300_ciae054-B8","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/inthealth\/ihx038","article-title":"For as long as necessary: examining 30 years of MSD's focus on achieving elimination of onchocerciasis and lymphatic filariasis","volume":"10","author":"Gustavsen","year":"2018","journal-title":"Int Health"},{"key":"2024042516222799300_ciae054-B9","author":"World Health Organization and African Programme for Onchocerciasis Control"},{"key":"2024042516222799300_ciae054-B10","doi-asserted-by":"crossref","first-page":"i40","DOI":"10.1093\/inthealth\/ihx054","article-title":"Alternative treatment strategies to accelerate the elimination of onchocerciasis","volume":"10","author":"Boussinesq","year":"2018","journal-title":"Int Health"},{"key":"2024042516222799300_ciae054-B11","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.12688\/gatesopenres.13067.1","article-title":"The World Health Organization 2030 goals for onchocerciasis: insights and perspectives from mathematical modelling","volume":"3","author":"NTD Modelling Consortium Onchocerciasis Group","year":"2019","journal-title":"Gates Open Res"},{"key":"2024042516222799300_ciae054-B12","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(17)32844-1","article-title":"Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial","volume":"392","author":"Opoku","year":"2018","journal-title":"Lancet"},{"key":"2024042516222799300_ciae054-B13","doi-asserted-by":"crossref","first-page":"e0010079","DOI":"10.1371\/journal.pntd.0010079","article-title":"Effect of a single dose of 8 mg moxidectin or 150 \u03bcg\/kg ivermectin on O. volvulus skin microfilariae in a randomized trial: differences between areas in the Democratic Republic of the Congo, Liberia and Ghana and impact of intensity of infection","volume":"16","author":"Bakajika","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516222799300_ciae054-B14"},{"key":"2024042516222799300_ciae054-B15","doi-asserted-by":"crossref","first-page":"e0006837","DOI":"10.1371\/journal.pntd.0006837","article-title":"Creative use of the priority review voucher by public and not-for-profit actors delivers the first new FDA-approved treatment for river blindness in 20 years","volume":"12","author":"Olliaro","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516222799300_ciae054-B16","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14787210.2020.1792772","article-title":"Moxidectin: an oral treatment for human onchocerciasis","volume":"18","author":"Milton","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2024042516222799300_ciae054-B17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13071-015-0779-4","article-title":"The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the phase II clinical trial data","volume":"8","author":"Turner","year":"2015","journal-title":"Parasit Vectors"},{"key":"2024042516222799300_ciae054-B18","author":"World Health Organization and African Programme for Onchocerciasis Control"},{"key":"2024042516222799300_ciae054-B19","doi-asserted-by":"crossref","first-page":"20220277","DOI":"10.1098\/rstb.2022.0277","article-title":"Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?","volume":"378","author":"Kura","year":"2023","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"2024042516222799300_ciae054-B20","doi-asserted-by":"crossref","first-page":"e0007557","DOI":"10.1371\/journal.pntd.0007557","article-title":"Modelling exposure heterogeneity and density dependence in onchocerciasis using a novel individual-based transmission model, EPIONCHO-IBM: implications for elimination and data needs","volume":"13","author":"Hamley","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516222799300_ciae054-B21","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/infdis\/172.1.204","article-title":"Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Program in West Africa","volume":"172","author":"Plaisier","year":"1995","journal-title":"J Infect Dis"},{"key":"2024042516222799300_ciae054-B22","doi-asserted-by":"crossref","first-page":"e2452","DOI":"10.1371\/journal.pntd.0002452","article-title":"The cost of annual versus biannual community-directed treatment of onchocerciasis with ivermectin: Ghana as a case study","volume":"7","author":"Turner","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516222799300_ciae054-B23","author":"World Health Organization and African Programme for Onchocerciasis Control"},{"key":"2024042516222799300_ciae054-B24","doi-asserted-by":"crossref","first-page":"e0010005","DOI":"10.1371\/journal.pntd.0010005","article-title":"Pharmacokinetics of oral moxidectin in individuals with Onchocerca volvulus infection","volume":"16","author":"Tan","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516222799300_ciae054-B25","author":"World Bank"},{"key":"2024042516222799300_ciae054-B26","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jval.2019.03.021","article-title":"Adjusting for inflation and currency changes within health economic studies","volume":"22","author":"Turner","year":"2019","journal-title":"Value Health"},{"key":"2024042516222799300_ciae054-B27","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/cid\/cix1001","article-title":"Economic evaluations of mass drug administration: the importance of economies of scale and scope","volume":"66","author":"Turner","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024042516222799300_ciae054-B28","volume-title":"Making choices in health: WHO guide to cost-effectiveness analysis","author":"Tan-Torres Edejer","year":"2003"},{"key":"2024042516222799300_ciae054-B29","doi-asserted-by":"crossref","first-page":"e0008033","DOI":"10.1371\/journal.pntd.0008033","article-title":"Modelling for policy: the five principles of the Neglected Tropical Diseases Modelling Consortium","volume":"14","author":"Behrend","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516222799300_ciae054-B30","author":"McCulloch"},{"key":"2024042516222799300_ciae054-B31","author":"World Health Organization"},{"key":"2024042516222799300_ciae054-B32","author":"Milton","year":"2022"},{"key":"2024042516222799300_ciae054-B33","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/tmi.13241","article-title":"Economic evaluations of onchocerciasis interventions: a systematic review and research needs","volume":"24","author":"Turner","year":"2019","journal-title":"Trop Med Int Health"},{"key":"2024042516222799300_ciae054-B34"},{"key":"2024042516222799300_ciae054-B35","doi-asserted-by":"crossref","first-page":"e2953","DOI":"10.1371\/journal.pntd.0002953","article-title":"A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection","volume":"8","author":"Awadzi","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2024042516222799300_ciae054-B36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0140-6736(96)11094-1","article-title":"Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection","volume":"350","author":"Gardon","year":"1997","journal-title":"Lancet"},{"key":"2024042516222799300_ciae054-B37","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1705026","article-title":"A test-and-not-treat strategy for onchocerciasis in Loa loa-endemic areas","volume":"377","author":"Kamgno","year":"2017","journal-title":"New Engl J Med"},{"key":"2024042516222799300_ciae054-B38"},{"key":"2024042516222799300_ciae054-B39","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/tmi.13937","article-title":"Persistence of onchocerciasis and associated dermatologic and ophthalmic pathologies after 27 years of ivermectin mass drug administration in the middle belt of Ghana","volume":"28","author":"Otabil","year":"2023","journal-title":"Trop Med Int Health"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/Supplement_2\/S138\/57334368\/ciae054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/Supplement_2\/S138\/57334368\/ciae054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T16:32:29Z","timestamp":1714062749000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/Supplement_2\/S138\/7657831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":39,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2024,4,25]]},"published-print":{"date-parts":[[2024,4,25]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae054","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,15]]},"published":{"date-parts":[[2024,4,25]]}}}